CTKBCytek Biosciences, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +20% vs its 200-day average.
Moderately shorted, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CTKB is trading
Cytek Biosciences, Inc. is +36% over the past year while the S&P 500 is +16%: 20 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +20%
vs 200-day average · a clear uptrend
- RSI (14)
- 36
RSI (14) · neutral
- Below its 52-week high
- 8.2%
Below its 52-week high
Details›
- Last close2026-10-23
- $5.59
- 1 monthS&P 500 −0.94%
- −2.3%
- 1 yearS&P 500 +16%
- +36%
- 5 yearsS&P 500 +86%
- −77%
- vs 50-day average$5.14
- +8.8%
- 52-week high
- $6.09
- 52-week low
- $3.36
- Annualised volatility
- 66%
| Year | Return |
|---|---|
| 2026 (year to date) | +11% |
| 2025 | −22% |
| 2024 | −29% |
| 2023 | −11% |
| 2022 | −37% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 1 of 5 | −6.3% |
| Feb | 5 | 1 of 5 | −8.4% |
| Mar | 5 | 0 of 5 | −12% |
| Apr | 5 | 2 of 5 | −0.20% |
| May | 5 | 1 of 5 | −14% |
| Jun | 5 | 4 of 5 | +9.5% |
| Jul | 5 | 4 of 5 | +9.1% |
| Aug | 6 | 3 of 6 | −1.2% |
| Sep | 6 | 2 of 6 | −0.38% |
| Oct | 6 | 3 of 6 | −2.7% |
| Nov | 5 | 3 of 5 | +23% |
| Dec | 5 | 1 of 5 | −3.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.